US Drug Pricing Strategy Shifts: List Price Cuts and Net Price Dynamics
Key Questions
What changes is Novo Nordisk making to Ozempic's list price?
Novo Nordisk will reduce Ozempic's list price by 35% to approximately $675 per month starting next year. This targets patients in high-deductible plans where coinsurance is based on wholesale acquisition cost, though net revenue may remain unchanged if rebates decrease accordingly.
How widespread is GLP-1 drug use in the United States?
GLP-1 adoption has reached 11% of US adults amid rising demand for these therapies. Oral formulations and recent price reductions are further influencing market dynamics and patient access.
What adoption and savings have bevacizumab biosimilars achieved in Medicare Part B?
Biosimilar adoption for bevacizumab in Medicare Part B reached 61% by 2023, producing $84.5 million in savings. Uptake was higher in more deprived areas at 81% but lower in nonurban regions, highlighting varied diffusion patterns.
Novo Nordisk will cut Ozempic's list price by 35% to ~$675/month starting next year, a strategic move targeting high-deductible plan patients and coinsurance tied to WAC, though net revenue may stay flat if rebates shrink. GLP-1 adoption has surged to 11% of US adults, with oral versions and price cuts reshaping the market. Additionally, bevacizumab biosimilar adoption in Medicare Part B reached 61% by 2023, generating $84.5M in savings, with higher uptake in more deprived areas (81%) but lower in nonurban areas, underscoring biosimilar diffusion trends. These developments signal a shift in US pricing strategy that could influence broader list-vs-net price debates and NADAC benchmarks. Market access professionals should track implications for rebate negotiations and patient access.